TYK2/JAK1 mechanism of action remains high28 Apr 2020 16:26
"Furthermore, industry interest in the TYK2/JAK1 mechanism of action remains high, with multiple late-stage clinical trials ongoing and readouts expected during the next 12-18 months for the most advanced candidates in this class"
Subject to financing, the Company is targeting completion of preclinical development for each molecule in 2020.
In line with its business model, the Company continues to engage with potential partners with a view to securing commercial licences when they reach late preclinical or early clinical stages.
The Company expects to complete preclinical (IND-enabling) studies in late 2020, subject to successful progress and financing, and is conducting research to refine its clinical trial plans, including prioritisation of indications.
The Company's stated value-generating strategy is to secure commercial licences when its assets reach late preclinical or early clinical stages and management is engaged in initial discussions with several potential partners.
The Company remains fully focused on advancing its preclinical development programmes with SDC-1801 and SDC-1802, its TYK2/JAK1 inhibitor assets, with the goal of completing preclinical studies in late 2020, subject to successful progress and financing.
The Company believes these are both high-quality assets that will prove attractive to potential partners, leading to licensing agreement(s) at late preclinical or early clinical stage.
Https://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/half-year-report/202003260700026313H/
Sign In
Follow the stocks
